MTOR and prostate cancer: In prostate cancer, increased ALDH1A3 activated the phosphatidylinositol 3-kinase/Protein kinase B/rapamycin (PI3K/AKT/mTOR) signaling pathway conferred a survival advantage to prostate cancer cells and decreasing their sensitivity to docetaxel (Figure 1) [71].